{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:21:40Z","timestamp":1792790500429,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jacc.2024.05.069","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T10:08:17Z","timestamp":1724666897000},"page":"904-917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes"],"prefix":"10.1016","volume":"84","author":[{"given":"Rohan","family":"Khera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3197-2657","authenticated-orcid":false,"given":"Arya","family":"Aminorroaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovedeep Singh","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis M.","family":"Thangaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Pedroso Camargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Bu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara V.","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faaizah","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clair","family":"Blacketer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shounak","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Dorr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talita","family":"Duarte-Salles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott L.","family":"DuVall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth E.","family":"Hanchrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2320-0470","authenticated-orcid":false,"given":"Wallis C.Y.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuntian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5264-2169","authenticated-orcid":false,"given":"Yuan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K.C.","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Matheny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestoras","family":"Mathioudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody-Ann","family":"McLeggon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"McLemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Minty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ostropolets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pistillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh-Phuc","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Pratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlen","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Seager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Viernes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seng Chan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin J.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick B.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn J.","family":"Schuemie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harlan M.","family":"Krumholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Hripcsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Suchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2024.05.069_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/2047487319880040","article-title":"Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases","volume":"26","author":"Prattichizzo","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacc.2024.05.069_bib2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.069_bib3","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib4","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib6","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib7","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.069_bib9","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib10","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2024.05.069_bib11","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib12","doi-asserted-by":"crossref","first-page":"706","DOI":"10.2337\/dc16-1943","article-title":"Sulfonylureas and the risks of cardiovascular events and death: A methodological meta-regression analysis of the observational studies","volume":"40","author":"Azoulay","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2024.05.069_bib13","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2024.05.069_bib14","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.05.069_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/dom.12821","article-title":"Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data","volume":"19","author":"Bain","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2024.05.069_bib16","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc24-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2024.05.069_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2024.05.069_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2023-000651","article-title":"Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM","volume":"2","author":"Khera","year":"2023","journal-title":"BMJ Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm \u2013 2020 executive summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacc.2024.05.069_bib20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.eprac.2022.08.002","article-title":"American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan\u20142022 update","volume":"28","author":"Blonde","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacc.2024.05.069_bib21","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/s41591-023-02502-5","article-title":"Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine","volume":"29","author":"Tobias","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib22","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijcard.2022.01.042","article-title":"Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice","volume":"352","author":"Fu","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.069_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","article-title":"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2024.05.069_bib25","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3389\/fendo.2020.00178","article-title":"GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials","volume":"11","author":"Gilbert","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jacc.2024.05.069_bib26","article-title":"Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus","volume":"10","author":"Nargesi","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2024.05.069_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057977","article-title":"Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies","volume":"12","author":"Khera","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2024.05.069_bib28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/amiajnl-2011-000376","article-title":"Validation of a common data model for active safety surveillance research","volume":"19","author":"Overhage","year":"2012","journal-title":"J\u00a0Am Med Inform Assoc"},{"key":"10.1016\/j.jacc.2024.05.069_bib29","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1038\/s41591-019-0597-x","article-title":"Avoidable flaws in observational analyses: an application to statins and cancer","volume":"25","author":"Dickerman","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib30","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacc.2024.05.069_bib31","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/S0140-6736(19)32317-7","article-title":"Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis","volume":"394","author":"Suchard","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2024.05.069_bib32","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2024.05.069_bib33","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1001\/jama.2020.16167","article-title":"Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"324","author":"You","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2024.05.069_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.diabres.2017.04.004","article-title":"Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents","volume":"128","author":"Wang","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacc.2024.05.069_bib35","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40264-020-00950-3","article-title":"Channeling bias in the analysis of risk of myocardial infarction, stroke, gastrointestinal bleeding, and acute renal failure with the use of paracetamol compared with ibuprofen","volume":"43","author":"Weinstein","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.jacc.2024.05.069_bib36","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/dom.13115","article-title":"Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study","volume":"20","author":"Yuan","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2024.05.069_bib37","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/jamia\/ocaa103","article-title":"Principles of Large-Scale Evidence Generation and Evaluation Across a Network of Databases (LEGEND)","volume":"27","author":"Schuemie","year":"2020","journal-title":"J\u00a0Am Med Inform Assoc"},{"key":"10.1016\/j.jacc.2024.05.069_bib38","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/ije\/dyy120","article-title":"Evaluating large-scale propensity score performance through real-world and synthetic data experiments","volume":"47","author":"Tian","year":"2018","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jacc.2024.05.069_bib39","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1073\/pnas.1708282114","article-title":"Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data","volume":"115","author":"Schuemie","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacc.2024.05.069_bib40","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1002\/sim.6977","article-title":"Robust empirical calibration of p-values using observational data","volume":"35","author":"Schuemie","year":"2016","journal-title":"Stat Med"},{"issue":"2128","key":"10.1016\/j.jacc.2024.05.069_bib41","article-title":"Improving reproducibility by using high-throughput observational studies with empirical calibration","volume":"376","author":"Schuemie","year":"2018","journal-title":"Philos Trans A Math Phys Eng Sci"},{"issue":"1","key":"10.1016\/j.jacc.2024.05.069_bib42","article-title":"How confident are we about observational findings in healthcare: a benchmark study","volume":"2","author":"Schuemie","year":"2020","journal-title":"Harv Data Sci Rev"},{"key":"10.1016\/j.jacc.2024.05.069_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.jacc.2024.05.069_bib46","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib47","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jbi.2016.12.005","article-title":"Accuracy of an automated knowledge base for identifying drug adverse reactions","volume":"66","author":"Voss","year":"2017","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.jacc.2024.05.069_bib48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jacc.2024.05.069_bib49","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2024.05.069_bib50","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2024.05.069_bib51","doi-asserted-by":"crossref","first-page":"751","DOI":"10.7326\/M22-2751","article-title":"Primary occurrence of cardiovascular events after adding sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists compared with dipeptidyl peptidase-4 inhibitors: a cohort study in veterans with diabetes","volume":"176","author":"Richardson","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib52","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.2337\/dc23-0671","article-title":"Comparative cardiovascular effectiveness and safety of SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors according to frailty in type 2 diabetes","volume":"46","author":"Kutz","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2024.05.069_bib53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12933-020-01078-5","article-title":"Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study","volume":"19","author":"Thein","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2024.05.069_bib54","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.36613","article-title":"Second-line pharmaceutical treatments for patients with type 2 diabetes","volume":"6","author":"Vashisht","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2024.05.069_bib55","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records","volume":"11","author":"Xie","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2024.05.069_bib56","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2337\/dc22-1238","article-title":"Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nationwide population-based comparative safety study","volume":"46","author":"Wang","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2024.05.069_bib57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","article-title":"American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm\u20142023 Update","volume":"29","author":"Samson","year":"2023","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacc.2024.05.069_bib58","article-title":"Multinational patterns of second-line anti-hyperglycemic drug initiation across cardiovascular risk groups: a federated pharmacoepidemiologic evaluation in LEGEND-T2DM","author":"Khera","year":"2022","journal-title":"Preprint 22283968. medRxiv"},{"key":"10.1016\/j.jacc.2024.05.069_bib59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","article-title":"Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA","volume":"139","author":"McGuire","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.069_bib60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.diabet.2016.09.005","article-title":"Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials","volume":"43","author":"Rehman","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jacc.2024.05.069_bib61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ijcard.2017.12.039","article-title":"Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs","volume":"254","author":"Fei","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.069_bib62","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2024.05.069_bib63","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2024.05.069_bib64","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ijcard.2015.03.075","article-title":"Use of electronic health records to ascertain, validate and phenotype acute myocardial infarction: a systematic review and recommendations","volume":"187","author":"Rubbo","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2024.05.069_bib65","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/pds.3921","article-title":"Validation of methods for assessing cardiovascular disease using electronic health data in a cohort of veterans with diabetes","volume":"25","author":"Floyd","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2024.05.069_bib66","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40264-018-0754-z","article-title":"Diagnostic algorithms for cardiovascular death in administrative claims databases: a systematic review","volume":"42","author":"Singh","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.jacc.2024.05.069_bib67","series-title":"Registries for Evaluating Patient Outcomes: A User\u2019s Guide","year":"2020"},{"key":"10.1016\/j.jacc.2024.05.069_bib68","series-title":"Tools and Technologies for Registry Interoperability, Registries for Evaluating Patient Outcomes: A User\u2019s Guide","author":"Gliklich","year":"2019"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724077799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109724077799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:35:08Z","timestamp":1756859708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109724077799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0735109724077799"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2024.05.069","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.05.24302354","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2024.05.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 the American College of Cardiology Foundation. Published by Elsevier. All rights are reserved, including those for text and data mining, AI training, and similar technologies","name":"copyright","label":"Copyright"}]}}